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Lattice corneal dystrophy gelsolin type was first described in 1969 by Jouko Meretoja, a Finnish ophthalmologist. It is caused
by an autosomal dominant mutation in gelsolin gene resulting in unstable protein fragments and amyloid deposition in various
organs. The age of onset is usually after the third decade of life and typical diagnostic triad includes progressive bilateral facial
paralysis, loose skin, and lattice corneal dystrophy. We report a case of a 53-year-old female patient referred to our Department of
Ophthalmology by severe dry eye and incomplete eyelid closure. She had severe bilateral facial paresis, significant orbicularis, and
perioral sagging as well as hypoesthesia of extremities and was diagnosed with Meretoja’s syndrome at the age of 50, confirmed by
the presence of gelsolinmutation. At our observation she had bilateral diminished tear film break-up time and Schirmer test, diffuse
keratitis, corneal opacification, and neovascularization in the left eye. She was treated with preservative-free lubricants and topical
cyclosporine, associated with nocturnal complete occlusion of both eyes, and underwent placement of lacrimal punctal plugs.
Ocular symptoms are the first to appear and our role as ophthalmologists is essential for the diagnosis, treatment, and monitoring
of ocular alterations in these patients.
1. Introduction
Amyloidosis is a group of diseases that can be divided into
localized or systemic and the etiology is primary, secondary,
or hereditary. Lattice corneal dystrophy, gelsolin type—
Meretoja’s syndrome—is also called lattice corneal dystrophy
type 2 (LCD2) or familial amyloidotic polyneuropathy (FAP)
type IV and is an autosomal dominant inherited disease
caused by amutation G654A or G654T in the gelsolin gene at
9q32–34 [1–3]. The biochemical analyses have indicated that
the amyloid fibrils formation is related to mutant gelsolin [4]
and amyloid deposition is found in various tissues such as
cornea, skin, vascular walls, and perineurium [5, 6]. It was
first described in 1969 by Dr. Meretoja, a Finnish ophthal-
mologist [7], and since then some cases in a limited number
of countries have been reported [8], probably because the
disease is underdiagnosed or misdiagnosed [9–11]. The age
of onset is usually after the third decade of life and the
first sign of the disease is a corneal lattice dystrophy [7,
12]. Typical diagnostic triad includes progressive bilateral
facial paralysis, loose skin (cutis laxa), and lattice corneal
dystrophy [1, 12].The ophthalmologic manifestations include
dry eye, irritation, and increased sensitivity to light. Other
reported manifestations are exposure keratopathy, dysfunc-
tion of the meibomian glands, early cataract development,
and an increased risk of secondary chronic open-angle
glaucoma [7, 12, 13]. It is believed that increased intraocular
pressure (IOP) is due to the effect of mutated gelsolin in
the trabecular muscle cells; no amyloid deposits were found
in the trabecular meshwork [13]. Facial paralysis and loose
skin affect eye lid closure and can cause ectropion leading
to corneal exposure with corneal ulcers, sometimes requiring
plastic surgery [14, 15].
2. Case Report
A 53-year-old female patient was referred to our department
by severe dry eye and incomplete eyelid closure. At the
age of 45 years the only symptom was a mild dry eye
medicated with ocular lubricants, but then she began to
realize she had difficulty in frowning. She was diagnosed
with Meretoja’s syndrome at the age of 50 after a bilateral
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Figure 1: Incomplete eyelid closure.
Figure 2: Inferior keratitis.
facial paresis and the diagnose was confirmed by the presence
of gelsolin mutation (G654A). The patient was from the
north coast of Portugal and had positive family history:
her mother had the disease. She had no knowledge of any
ancestor from Finland. When the patient was referred to our
Ophthalmology Department she had severe bilateral facial
palsy, with significant orbicularis and perioral sagging as well
as hypoesthesia of extremities. On neurological examination
we observed marked facial diparesis, tongue fasciculations,
hypoesthesia in the median nerve territory bilaterally, brisk
tendon reflexes, and normal coordination tests. Nerve con-
duction studies revealed slow (median, ulnar, radial, super-
ficial, and sural peroneal nerves) sensitive and motor nerve
fibers conduction.Needle electromyographywas normal. Left
plantar and palmar sympathetic skin responses were absent
on electrical stimulation, indicating sympathetic sudomotor
fibers involvement. Heart rate response to deep breathing
was unremarkable. Quantitative sensory test revealed an
increased sensitivity threshold to the vibratory stimuli and
hypersensitivity to heat but normal results to cold stimula-
tion.
At our observation, she had an incomplete eyelid closure
specially in the right eye (Figure 1) and decreased blinking
reflex; the best corrected visual acuity (BCVA) was 0.6
bilaterally (decimal scale) and the slit lamp examination
showed a diminished tear film break-up time (less than 5
seconds), a diffuse keratitis (Figure 2), corneal haze with lin-
ear subepithelial opacities in the anterior stroma of both eyes
(Figure 3), and a corneal leukoma with neovascularization
in the left eye (Figure 4). Schirmer test was 8 and 9mm,
respectively. IOP was 12mmHg and 10mmHg, respectively,
and fundus observation showed no alterations. She was
medicated with preservative-free lubricants associated with
nocturnal complete occlusion of both eyes. Three months
Figure 3: Corneal haze with linear subepithelial opacities in the
anterior stroma.
Figure 4: Corneal opacification with neovascularization.
later, despite symptomatic improvement, the ocular surface
remained quite similar and the patient was treated with
topical cyclosporine at the concentration of 0.05%, 1 drop
twice daily (twelve hours apart). Ten months after treatment
there was an improvement in right eye BCVA (0.8); the
slit lamp examination showed bilateral central stromal haze,
no keratitis in the right eye, and improvement in the left
eye. In the next 3 months there was a worsening of the
ocular discomfort and at observation she had a bilateral
inferior keratitis with a corneal erosion in the right eye. A
temporary lateral tarsorrhaphy was proposed, but the patient
refused it. She underwent bilateral lacrimal punctal plugs
placement and at the end of the follow-up—6 months after
plugs placement—the BCVA was 0.8 in the right eye and 0.6
in the left eye; at slit lamp examination there is no keratitis
or corneal erosions and a lower degree of haze and there was
some regression of corneal vessels in the left eye.The IOPwas
18mmHg and 16mmHg, respectively, and fundoscopy was
normal.
3. Discussion
Meretoja’s syndrome is a rare conditionwith severe and debil-
itating ocular manifestations and the diagnosis is typically
made by observation of the corneal lattice dystrophy [16].
Dry eye syndrome is one of themost commonmanifestations
and is caused by the involvement of several cranial nerves—
decreased blink reflex (trigeminal nerve) and weak contrac-
tion of the orbicularis muscle (facial nerve). Cutis laxa and
peripheral facial paralysis can cause ectropion contributing
to a worsening of the problem [7, 12, 13, 15]. Treatment is
symptomatic with topical lubricants, anti-inflammatory ther-
apy, hydrophilic contact lenses, and occlusion of the lacrimal
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ductswith plugs. In themost severe cases surgical treatment is
required; eyelid surgery (tarsorrhaphy, ectropion correction)
or even penetrating keratoplasty is some of the options, but
most often with poor prognosis [13, 15]. Ocular symptoms
are the first to appear and our role as ophthalmologists
is essential in the diagnosis, treatment, and monitoring of
ocular alterations. These patients should have regular oph-
thalmologic checkups to maintain a healthy ocular surface
and avoid severe corneal damage with irreversible visual loss,
also allowing early detection of other severe complications
such as glaucoma.
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